Warrack Bethanne M, Hnatyshyn Serhiy, Ott Karl-Heinz, Reily Michael D, Sanders Mark, Zhang Haiying, Drexler Dieter M
Bristol-Myers Squibb Company, Research and Development, USA.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):547-52. doi: 10.1016/j.jchromb.2009.01.007. Epub 2009 Jan 14.
Unlike plasma and most biological fluids which have solute concentrations that are tightly controlled, urine volume can vary widely based upon water consumption and other physiological factors. As a result, the concentrations of endogenous metabolites in urine vary widely and normalizing for these effects is necessary. Normalization approaches that utilized urine volume, osmolality, creatinine concentration, and components that are common to all samples ("total useful MS signal") were compared in order to determine which strategies could be successfully used to differentiate between dose groups based upon the complete endogenous metabolite profile. Variability observed in LC/MS results obtained from targeted and non-targeted metabonomic analyses was highly dependent on the strategy used for normalization. We therefore recommend the use of two different normalization techniques in order to facilitate detection of statistically significant changes in the endogenous metabolite profile when working with urine samples.
与血浆和大多数生物体液不同,它们的溶质浓度受到严格控制,而尿量会因水的摄入量和其他生理因素而有很大差异。因此,尿液中内源性代谢物的浓度差异很大,对这些影响进行标准化是必要的。比较了利用尿量、渗透压、肌酐浓度以及所有样本共有的成分(“总有用质谱信号”)的标准化方法,以确定哪些策略可成功用于根据完整的内源性代谢物谱区分剂量组。从靶向和非靶向代谢组学分析获得的液相色谱/质谱结果中观察到的变异性高度依赖于所使用的标准化策略。因此,我们建议使用两种不同的标准化技术,以便在处理尿液样本时便于检测内源性代谢物谱中的统计学显著变化。